Novelion Therapeutics Inc. (NASDAQ:NVLN) Files An 8-K Results of Operations and Financial Condition
Item 2.02 Results of Operations and Financial Condition.

On November 9, 2017, Novelion Therapeutics Inc. announced its financial results for the quarter ended September 30, 2017. A copy of the press release is being furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in this Form 8-K and Exhibit 99.1 attached hereto is intended to be furnished and shall not be deemed “filed” for purposes of Section18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 2.02 Financial Statements and Exhibits.

(d) Exhibits:

The following exhibit shall be deemed to be furnished, and not filed:

99.1Press Release dated November 9, 2017

EXHIBIT INDEX

NOVELION THERAPEUTICS INC. Exhibit
EX-99.1 2 a093017earningsrelease_exh.htm EXHIBIT 99.1 Exhibit Exhibit 99.1Novelion Therapeutics Reports Third Quarter 2017 Financial Results and Announces Leadership Change•Company Reiterates FY 2017 Guidance for Total Net Revenues of $135-$145 million •Company Announces Leadership Change and Search for Chief Executive Officer VANCOUVER,…
To view the full exhibit click here

About Novelion Therapeutics Inc. (NASDAQ:NVLN)

Novelion Therapeutics Inc, formerly QLT Inc., is a Canada-based biopharmaceutical company. The Company is engaged in development of new standards of care for individuals living with rare diseases. The Company is focused on advancing its portfolio of rare disease therapies by investing in science and clinical development. The Company holds a portfolio of products through its subsidiary, Aegerion Pharmaceuticals, Inc., a biopharmaceutical company dedicated to the development and commercialization of innovative therapies for patients with debilitating rare diseases. The Company’s portfolio of products include MYALEPT and JUXTAPID. The Company is also developing zuretinol acetate for the treatment of inherited retinal disease caused by underlying mutations in RPE65 or LRAT genes.